OncoCyte Corporation (OCX)
| Bid | 3 |
| Market Cap | 88.28M |
| Revenue (ttm) | 3.84M |
| Net Income (ttm) | -58.2M |
| EPS (ttm) | -3.79 |
| PE Ratio (ttm) | -0.81 |
| Forward PE | -2.84 |
| Analyst | Buy |
| Ask | 3.14 |
| Volume | 35,842 |
| Avg. Volume (20D) | 43,741 |
| Open | 2.77 |
| Previous Close | 2.73 |
| Day's Range | 2.82 - 3.15 |
| 52-Week Range | 1.92 - 4.75 |
| Beta | 0.99 |
Analyst Forecast
According to 0 analyst ratings, the average rating for OCX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
2 months ago · prismmediawire.com
Oncocyte to Participate in 24th Annual Needham Virtual Healthcare ConferenceIRVINE, Calif., April 2, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Of...
2 months ago · prismmediawire.com
Oncocyte Reports Successful 2024; Sets Stage for 2025 CatalystsIRVINE, Calif., March 24, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its fourth q...
3 months ago · prismmediawire.com
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025IRVINE, Calif., March 18, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results ...